Float Short %

37.26

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

0.05

EPS Last/This Y

0.11

EPS This/Next Y

0.31

Price

4.83

Target Price

6.47

Analyst Recom

2.5

Performance Q

-6.58

Relative Volume

0.69

Beta

0.91

Ticker: RXRX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	RXRX	5.77	0.43	0.35	431437
2025-08-18	RXRX	5.53	0.42	0.16	396481
2025-08-19	RXRX	5.09	0.42	0.41	406176
2025-08-20	RXRX	4.76	0.42	0.60	409651
2025-08-21	RXRX	4.77	0.42	0.18	417255
2025-08-22	RXRX	4.94	0.42	0.22	420943
2025-08-25	RXRX	4.84	0.42	0.23	410975
2025-08-26	RXRX	4.84	0.42	0.16	420047
2025-08-27	RXRX	4.89	0.42	0.17	421926
2025-08-28	RXRX	4.86	0.41	0.12	423722
2025-08-29	RXRX	4.7	0.41	0.49	425303
2025-09-02	RXRX	4.66	0.42	0.21	412750
2025-09-03	RXRX	4.64	0.41	0.21	418455
2025-09-04	RXRX	4.52	0.41	0.25	421274
2025-09-05	RXRX	4.61	0.41	0.24	423791
2025-09-08	RXRX	4.62	0.41	0.23	417059
2025-09-09	RXRX	4.71	0.41	0.14	420220
2025-09-10	RXRX	4.54	0.41	0.26	423425
2025-09-11	RXRX	4.86	0.41	0.03	426012
2025-09-12	RXRX	4.82	0.37	0.07	452844
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	RXRX	5.76	0.0	-	-1.55
2025-08-18	RXRX	5.51	0.0	-	-1.55
2025-08-19	RXRX	5.09	0.0	-	-1.55
2025-08-20	RXRX	4.76	-7.3	-	-1.55
2025-08-21	RXRX	4.77	-7.3	-	-1.55
2025-08-22	RXRX	4.94	-7.3	-	-1.58
2025-08-25	RXRX	4.84	-7.3	-	-1.58
2025-08-26	RXRX	4.83	-7.3	-	-1.58
2025-08-27	RXRX	4.89	-7.3	-	-1.58
2025-08-28	RXRX	4.86	-7.3	-	-1.58
2025-08-29	RXRX	4.70	-7.3	-	-1.58
2025-09-02	RXRX	4.66	-7.3	-	-1.58
2025-09-03	RXRX	4.63	-7.3	-	-1.58
2025-09-04	RXRX	4.51	-7.3	-	-1.58
2025-09-05	RXRX	4.61	-7.3	-	-1.58
2025-09-08	RXRX	4.62	-7.3	-	-1.58
2025-09-09	RXRX	4.71	-7.3	-	-1.58
2025-09-10	RXRX	4.55	-7.3	-	-1.58
2025-09-11	RXRX	4.85	-7.3	-	-1.58
2025-09-12	RXRX	4.83	-7.3	-	-1.58
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	RXRX	-0.77	-2.75	35.39
2025-08-18	RXRX	-0.77	-1.19	35.38
2025-08-19	RXRX	-0.78	-1.19	35.38
2025-08-20	RXRX	-0.81	-1.19	35.38
2025-08-21	RXRX	-0.81	-1.19	35.38
2025-08-22	RXRX	-0.81	-1.19	35.42
2025-08-25	RXRX	-0.81	-1.53	35.37
2025-08-26	RXRX	-0.81	-1.53	35.37
2025-08-27	RXRX	-0.81	-1.53	36.78
2025-08-28	RXRX	-0.81	-1.53	36.78
2025-08-29	RXRX	-0.91	-1.53	36.78
2025-09-02	RXRX	-0.91	-1.41	36.78
2025-09-03	RXRX	-0.91	-1.41	36.78
2025-09-04	RXRX	-0.91	-1.41	36.78
2025-09-05	RXRX	-0.91	-1.41	36.71
2025-09-08	RXRX	-0.87	-1.42	36.71
2025-09-09	RXRX	-0.87	-1.42	36.71
2025-09-10	RXRX	-0.87	-1.42	36.71
2025-09-11	RXRX	-0.87	-1.42	37.26
2025-09-12	RXRX	-0.97	-1.42	37.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.41

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.36

Insider Transactions

-0.97

Institutional Transactions

-1.42

Beta

0.91

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.7

Max Drawdown 5-Year %

Target Price

6.47

P/E

Forward P/E

PEG

P/S

32.5

P/B

2.27

P/Free Cash Flow

EPS

-1.79

Average EPS Est. Cur. Y

-1.58

EPS Next Y. (Est.)

-1.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1004.91

Relative Volume

0.69

Return on Equity vs Sector %

-95.5

Return on Equity vs Industry %

-82.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.12

EBIT Estimation

Recursion Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today

news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance

stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market

stock prices RXRX premarket after hours

ticker RXRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y